These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 33332284)

  • 1. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.
    Balança CC; Salvioni A; Scarlata CM; Michelas M; Martinez-Gomez C; Gomez-Roca C; Sarradin V; Tosolini M; Valle C; Pont F; Ferron G; Gladieff L; Vergez S; Dupret-Bories A; Mery E; Rochaix P; Fournié JJ; Delord JP; Devaud C; Martinez A; Ayyoub M
    JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33332284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
    Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
    J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.
    Sawada M; Goto K; Morimoto-Okazawa A; Haruna M; Yamamoto K; Yamamoto Y; Nakagawa S; Hiramatsu K; Matsuzaki S; Kobayashi E; Kawashima A; Hirata M; Iwahori K; Kimura T; Ueda Y; Kimura T; Wada H
    Int Immunol; 2020 May; 32(6):397-405. PubMed ID: 32009163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
    Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
    Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral Tcf1
    Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
    Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of tumor-reactive CD4
    Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
    Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
    Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-Checkpoint Blockade Opposes CD8
    Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
    Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 Status in CD8
    Kansy BA; Concha-Benavente F; Srivastava RM; Jie HB; Shayan G; Lei Y; Moskovitz J; Moy J; Li J; Brandau S; Lang S; Schmitt NC; Freeman GJ; Gooding WE; Clump DA; Ferris RL
    Cancer Res; 2017 Nov; 77(22):6353-6364. PubMed ID: 28904066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39
    Leem G; Park J; Jeon M; Kim ES; Kim SW; Lee YJ; Choi SJ; Choi B; Park S; Ju YS; Jung I; Kim S; Shin EC; Lee JY; Park SH
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased PD-1
    Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
    Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
    Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
    Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Effector Phenotype of Tim-3
    Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
    Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
    [No Abstract]   [Full Text] [Related]  

  • 16. Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs.
    Eiva MA; Omran DK; Chacon JA; Powell DJ
    Eur J Immunol; 2022 Jan; 52(1):96-108. PubMed ID: 34505280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subsets of exhausted CD8
    Miller BC; Sen DR; Al Abosy R; Bi K; Virkud YV; LaFleur MW; Yates KB; Lako A; Felt K; Naik GS; Manos M; Gjini E; Kuchroo JR; Ishizuka JJ; Collier JL; Griffin GK; Maleri S; Comstock DE; Weiss SA; Brown FD; Panda A; Zimmer MD; Manguso RT; Hodi FS; Rodig SJ; Sharpe AH; Haining WN
    Nat Immunol; 2019 Mar; 20(3):326-336. PubMed ID: 30778252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer.
    Wang Y; Wang C; Qiu J; Qu X; Peng J; Lu C; Zhang M; Zhang M; Qi X; Li G; Hua K
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.